Published in Am J Kidney Dis on October 31, 2009
VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med (2008) 9.87
The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification. Kidney Int (2009) 7.45
The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility. Kidney Int (2009) 7.19
APOL1 risk variants, race, and progression of chronic kidney disease. N Engl J Med (2013) 5.00
Pathologic classification of diabetic nephropathy. J Am Soc Nephrol (2010) 3.61
Apolipoprotein L1 gene variants associate with hypertension-attributed nephropathy and the rate of kidney function decline in African Americans. Kidney Int (2012) 3.46
C3 glomerulopathy: consensus report. Kidney Int (2013) 2.85
Monomorphous angiocentric glioma: a distinctive epileptogenic neoplasm with features of infiltrating astrocytoma and ependymoma. J Neuropathol Exp Neurol (2005) 2.58
Plasmapheresis, CMV hyperimmune globulin, and anti-CD20 allow ABO-incompatible renal transplantation without splenectomy. Am J Transplant (2004) 2.22
The Oxford IgA nephropathy clinicopathological classification is valid for children as well as adults. Kidney Int (2010) 2.14
Pros and cons for C4d as a biomarker. Kidney Int (2012) 2.03
Biodistribution, tumor detection, and radiation dosimetry of 18F-DCFBC, a low-molecular-weight inhibitor of prostate-specific membrane antigen, in patients with metastatic prostate cancer. J Nucl Med (2012) 2.00
Immunoexpression status and prognostic value of mTOR and hypoxia-induced pathway members in primary and metastatic clear cell renal cell carcinomas. Am J Surg Pathol (2011) 1.76
ABO incompatible renal transplantation: a paradigm ready for broad implementation. Transplantation (2009) 1.71
Design of the Nephrotic Syndrome Study Network (NEPTUNE) to evaluate primary glomerular nephropathy by a multidisciplinary approach. Kidney Int (2013) 1.69
Administration of a soluble recombinant complement C3 inhibitor protects against renal disease in MRL/lpr mice. J Am Soc Nephrol (2003) 1.68
Immunotactoid keratopathy: a clinicopathologic case report and a review of reports of corneal involvement in systemic paraproteinemias. Surv Ophthalmol (2004) 1.67
Eculizumab and splenectomy as salvage therapy for severe antibody-mediated rejection after HLA-incompatible kidney transplantation. Transplantation (2014) 1.62
Geometric evaluation of systematic transrectal ultrasound guided prostate biopsy. J Urol (2012) 1.59
Transcription factor Nrf2 is protective during ischemic and nephrotoxic acute kidney injury in mice. Kidney Int (2009) 1.56
Injury in renal ischemia-reperfusion is independent from immunoglobulins and T lymphocytes. Am J Physiol Renal Physiol (2002) 1.45
Renal medullary carcinoma: clinical, pathologic, immunohistochemical, and genetic analysis with pathogenetic implications. Urology (2002) 1.44
Anti-vascular endothelial growth factor receptor-2 antibody accelerates renal disease in the NZB/W F1 murine systemic lupus erythematosus model. Clin Cancer Res (2005) 1.44
Successful retransplantation after renal allograft loss to polyoma virus interstitial nephritis. Transplantation (2002) 1.43
High-dose mycophenolate mofetil in the treatment of posttransplant glomerular disease in the allograft: a case series. Nephron Clin Pract (2004) 1.40
Case of hereditary papillary renal cell carcinoma. J Community Hosp Intern Med Perspect (2012) 1.39
The effects of vitamin C supplementation on serum concentrations of uric acid: results of a randomized controlled trial. Arthritis Rheum (2005) 1.29
KDOQI US commentary on the 2012 KDIGO clinical practice guideline for glomerulonephritis. Am J Kidney Dis (2013) 1.29
B cell gene signature with massive intrahepatic production of antibodies to hepatitis B core antigen in hepatitis B virus-associated acute liver failure. Proc Natl Acad Sci U S A (2010) 1.26
Abatacept in B7-1-positive proteinuric kidney disease. N Engl J Med (2014) 1.26
Chronic administration of valproic acid inhibits prostate cancer cell growth in vitro and in vivo. Cancer Res (2006) 1.24
Renal cell carcinoma seeding of a percutaneous biopsy tract. Can Urol Assoc J (2013) 1.17
Complement factor H deficiency accelerates development of lupus nephritis. J Am Soc Nephrol (2010) 1.16
C5a promotes development of experimental lupus nephritis which can be blocked with a specific receptor antagonist. Eur J Immunol (2005) 1.16
Late antibody-mediated rejection in renal allografts: outcome after conventional and novel therapies. Transplantation (2014) 1.16
Mouse podocyte complement factor H: the functional analog to human complement receptor 1. J Am Soc Nephrol (2007) 1.16
Anti-angiotensin type 1 receptor antibodies associated with antibody mediated rejection in donor HLA antibody negative patients. Transplantation (2010) 1.15
Sarcoidosis: the nephrologist's perspective. Am J Kidney Dis (2006) 1.14
Integrin alpha(v) and coxsackie adenovirus receptor expression in clinical bladder cancer. Urology (2002) 1.10
Specific and durable elimination of antibody to donor HLA antigens in renal-transplant patients. Transplantation (2003) 1.10
Antibody-mediated rejection in renal allografts: lessons from pathology. Clin J Am Soc Nephrol (2006) 1.09
Signaling through up-regulated C3a receptor is key to the development of experimental lupus nephritis. J Immunol (2005) 1.08
Renal biopsy in lupus patients with low levels of proteinuria. J Rheumatol (2006) 1.07
Renal tumor ablation. Tech Vasc Interv Radiol (2013) 1.06
Successful renal transplantation across simultaneous ABO incompatible and positive crossmatch barriers. Am J Transplant (2004) 1.05
Unrestricted C3 activation occurs in Crry-deficient kidneys and rapidly leads to chronic renal failure. J Am Soc Nephrol (2007) 1.05
Cocaine use and hypertensive renal changes in HIV-infected individuals. Clin J Am Soc Nephrol (2007) 1.03
Case series: CTLA4-IgG1 therapy in minimal change disease and focal segmental glomerulosclerosis. Pediatr Nephrol (2014) 1.02
Prevalence of BRCA1 and BRCA2 mutations in breast cancer patients from Cuba. Fam Cancer (2008) 1.02
Valproic acid, a histone deacetylase inhibitor, is an antagonist for oncolytic adenoviral gene therapy. Mol Ther (2006) 1.01
Transgenic expression of a soluble complement inhibitor protects against renal disease and promotes survival in MRL/lpr mice. J Immunol (2002) 1.00
Primary alveolar soft part sarcoma (ASPS) of the breast: report of a deceptive case with xanthomatous features confirmed by TFE3 immunohistochemistry and electron microscopy. Int J Surg Pathol (2005) 0.99
Prostate-specific expression of the diphtheria toxin A chain (DT-A): studies of inducibility and specificity of expression of prostate-specific antigen promoter-driven DT-A adenoviral-mediated gene transfer. Cancer Res (2002) 0.97
CTL-promoting effects of CD40 stimulation outweigh B cell-stimulatory effects resulting in B cell elimination and disease improvement in a murine model of lupus. J Immunol (2008) 0.97
Effects of curcumin on bladder cancer cells and development of urothelial tumors in a rat bladder carcinogenesis model. Cancer Lett (2008) 0.97
Focal and segmental glomerulosclerosis induced in mice lacking decay-accelerating factor in T cells. J Clin Invest (2009) 0.96
Complement factor h limits immune complex deposition and prevents inflammation and scarring in glomeruli of mice with chronic serum sickness. J Am Soc Nephrol (2004) 0.95
Incidence and outcomes of BK virus allograft nephropathy among ABO- and HLA-incompatible kidney transplant recipients. Clin J Am Soc Nephrol (2012) 0.95
Valproic acid causes dose- and time-dependent changes in nuclear structure in prostate cancer cells in vitro and in vivo. Mol Cancer Ther (2009) 0.94
Benefits of rituximab combined with intravenous immunoglobulin for desensitization in kidney transplant recipients. Transplantation (2014) 0.93
Oxalate deposits in biopsies from native and transplanted kidneys, and impact on graft function. Nephrol Dial Transplant (2008) 0.93
Distinct roles for C3a and C5a in complement-induced tubulointerstitial injury. Kidney Int (2011) 0.93
A novel source for miR-21 expression through the alternative polyadenylation of VMP1 gene transcripts. Nucleic Acids Res (2012) 0.93
Decay-accelerating factor expression in the rat kidney is restricted to the apical surface of podocytes. Kidney Int (2002) 0.92
Androgen receptor attenuation of Ad5 replication: implications for the development of conditionally replication competent adenoviruses. Mol Ther (2007) 0.92
Hepatitis C virus and its renal manifestations: a review and update. Gastroenterol Hepatol (N Y) (2012) 0.92
Bartter syndrome complicated by immune complex nephropathy. Case report and literature review. Pediatr Nephrol (2003) 0.92
Safety and efficacy of CT-guided percutaneous cryoablation for renal cell carcinoma. J Vasc Interv Radiol (2008) 0.91
Valproic acid inhibits invasiveness in bladder cancer but not in prostate cancer cells. J Pharmacol Exp Ther (2006) 0.91
Recent advances and prognosis in idiopathic membranous nephropathy. Adv Chronic Kidney Dis (2012) 0.91
Time course of pathologic changes in kidney allografts of positive crossmatch HLA-incompatible transplant recipients. Transplantation (2014) 0.91
Determinants of outcomes after resection of renal cell carcinoma with venous involvement. Int Urol Nephrol (2012) 0.90
A novel method for generating and screening peptides and libraries displayed on adenovirus fiber. Nucleic Acids Res (2007) 0.90
Factors Predicting Risk for Antibody-mediated Rejection and Graft Loss in Highly Human Leukocyte Antigen Sensitized Patients Transplanted After Desensitization. Transplantation (2015) 0.90
Determination of the nonlethal margin inside the visible "ice-ball" during percutaneous cryoablation of renal tissue. Cardiovasc Intervent Radiol (2012) 0.89
Eculizumab for the treatment of two recurrences of atypical hemolytic uremic syndrome in a kidney allograft. Transpl Int (2012) 0.89
Excellent outcomes after transplantation of deceased donor kidneys with high terminal creatinine and mild pathologic lesions. Transplantation (2005) 0.88
Prostate stem cell antigen enhancer and uroplakin II promoter based bladder cancer targeted tissue-specific vector. Urol Oncol (2008) 0.88
A 66-year-old man with prostate-specific antigen recurrence and lung mass after radical prostatectomy. Urology (2012) 0.88
Obstructive nephropathy secondary to sulfasalazine calculi. Urology (2003) 0.88
A real time Metridia luciferase based non-invasive reporter assay of mammalian cell viability and cytotoxicity via the β-actin promoter and enhancer. PLoS One (2012) 0.88
Distinct and separable roles of the complement system in factor H-deficient bone marrow chimeric mice with immune complex disease. J Am Soc Nephrol (2006) 0.88
A Phase I/II Trial of the Interleukin-6 Receptor-Specific Humanized Monoclonal (Tocilizumab) + Intravenous Immunoglobulin in Difficult to Desensitize Patients. Transplantation (2015) 0.88
Angiotensin antibodies and focal segmental glomerulosclerosis. N Engl J Med (2013) 0.87
Donor CD8 T cell activation is critical for greater renal disease severity in female chronic graft-vs.-host mice and is associated with increased splenic ICOS(hi) host CD4 T cells and IL-21 expression. Clin Immunol (2010) 0.87
Histone deacetylase inhibitors upregulate expression of the coxsackie adenovirus receptor (CAR) preferentially in bladder cancer cells. Cancer Gene Ther (2004) 0.87
Increased negative impact of donor HLA-specific together with non-HLA-specific antibodies on graft outcome. Transplantation (2014) 0.87
Preoperative diagnosis of malignant mesothelioma of the tunica vaginalis using Doppler ultrasound. Urology (2009) 0.87
A phase I/II placebo-controlled trial of C1-inhibitor for prevention of antibody-mediated rejection in HLA sensitized patients. Transplantation (2015) 0.86
CR1/CR2 deficiency alters IgG3 autoantibody production and IgA glomerular deposition in the MRL/lpr model of SLE. Autoimmunity (2004) 0.86
Fas expression on antigen-specific T cells has costimulatory, helper, and down-regulatory functions in vivo for cytotoxic T cell responses but not for T cell-dependent B cell responses. J Immunol (2008) 0.86
Effects of acid aspiration-induced acute lung injury on kidney function. Am J Physiol Renal Physiol (2008) 0.85
Histopathologic features of transplant glomerulopathy associated with response to therapy with intravenous immune globulin and rituximab. Clin Transplant (2014) 0.85
Complications of renal cryoablation: a single center experience. J Urol (2010) 0.85
Disulfide-constrained peptides that bind to the extracellular portion of the prostate-specific membrane antigen. Mol Cancer Ther (2004) 0.85
Mechanism of growth inhibition of prostate cancer xenografts by valproic acid. J Biomed Biotechnol (2012) 0.85
Collapsing glomerulopathy in systemic lupus erythematosus: an extreme form of lupus podocytopathy? Clin J Am Soc Nephrol (2012) 0.84
Frailty, mycophenolate reduction, and graft loss in kidney transplant recipients. Transplantation (2015) 0.84
Transplant glomerulopathy: it's not always about chronic rejection. Kidney Int (2011) 0.84